Alcohol use and misuse are identified as a leading cause of prevention for disability and premature death in both developed and developing world.\[[@ref1]\] Alcohol use disorders (AUD) comprise spectrum of alcohol use behaviors ranging from the heavy drinking, alcohol abuse, and the more severe pattern of alcohol dependence. A nation-wide epidemiological study in India has reported prevalence 21.4% for "current use" of alcohol and of these at least 17% may be dependent users.\[[@ref2]\] Management of AUD provides best results when pharmacological and psychosocial interventions are combined.\[[@ref3][@ref4]\] Other than disulfiram, which is an aversive treatment, pharmacological treatment is needed during alcohol withdrawal state (including delirium and seizures) and to reduce craving after cessation of alcohol use.

The WHO defines craving as a strong desire or sense of compulsion to take the substance (either drugs or alcohol).\[[@ref5]\] Craving is recognized as a formidable barrier in the management of patients with alcohol dependence.\[[@ref6]\] The neurobiological underpinnings of craving are being discovered, and numerous possibilities for pharmacological management of craving are being postulated.\[[@ref7][@ref8][@ref9][@ref10]\]

Apart for the two widely used, the US-Food and Drug Administration approved, drugs acamprosate and naltrexone, many other agents have been used specifically for the management of craving. These include ondansetron,\[[@ref11][@ref12]\] buspirone,\[[@ref13]\] fluoxetine, and other selective serotonin reuptake inhibitors,\[[@ref14][@ref15]\] topiramate,\[[@ref16]\] and baclofen. Baclofen is primarily used to reduce spasticity due to variety of neurological disorders such as multiple sclerosis and cerebral palsy, in dose of 15--80 mg/day.\[[@ref17]\] Its agonistic action on metabotropic G-protein (GABAB) receptors makes it a useful agent in the management of craving.

Preclinical studies have shown baclofen to suppress alcohol-stimulated dopamine release and in turn, dopamine-mediated, alcohol-reinforced, and motivated behaviors.\[[@ref18]\] Clinical studies have demonstrated a reduction in alcohol withdrawal symptoms when baclofen is given either as prophylaxis or treatment.\[[@ref19][@ref20][@ref21]\] Furthermore, since baclofen is primarily eliminated unchanged by the kidneys (85%), it can be prescribed in the presence of alcohol liver diseases.\[[@ref17][@ref22]\] Anticraving efficacy studies of baclofen in humans have been conducted in few countries. Apart for one study,\[[@ref23]\] we are not aware of any systemic study for the baclofen use in India. In view of this, we used the drug with caution in our patients.

METHODOLOGY {#sec1-1}
===========

The study is a retrospective chart review of patients who received treatment for alcohol dependence syndrome between June 2009 and June 2010 (13 months) from the de-addiction clinic of a tertiary healthcare center in North India. As a standard protocol in the department since 2009, the patients of alcohol dependence are detoxified either with benzodiazepine alone or with baclofen. Benzodiazepine-based detoxification was preferred in those with a history of withdrawal seizures, in those with no prior history of benzodiazepine dependence, and those who had a good response to naltrexone, acamprosate, and topiramate as anticraving agents. After detoxification, patients detoxified with benzodiazepines are started on either of the craving reduction drugs, namely., naltrexone, acamprosate, or topiramate, whereas patients detoxified with baclofen are continued on the same drug as baclofen itself has shown anticraving efficacy. Patients are followed twice a week for 1^st^ 2 weeks and then weekly thereafter on outpatient basis. Patients admitted in the ward are detoxified and are generally discharged within 2 weeks. Pharmacotherapy for both outdoor and the indoor patients is largely same. In addition to pharmacotherapy, all the patients attended four group therapy sessions which are held once a week. The medical records of all the patients are stringently maintained and include personal details, drug use pattern, severity of dependence, level of motivation, severity of withdrawal, and degree of craving.

The inclusion criteria for the current study were: (1) patients with alcohol dependence syndrome diagnosed as per ICD-10, (2) age 18--65 years, and (3) patients with at least 1 week of baclofen use as per records. We included patients with additional diagnosis of substance use or other psychiatric and medical disorders, irrespective of their detoxification status, and treatment setup at the time of initiation of baclofen (inpatient/outpatient). We excluded those patients who were not accompanied by reliable informant at the time of initiation of treatment or doubtful compliance to therapy (as recorded in file).

For the purpose of the study, baseline assessment for socioepidemiological profile, substance use pattern, and treatment records was extracted from the records. As mentioned above, it is a practice in the department to record craving in terms of (a) no craving or minimal craving that can be easy to manage, noted "0" or "+" in records, (b) significant cue-associated craving that is often difficult to manage, noted "++" in records (henceforth called moderate craving), and (c) severe pervasive craving that cannot be managed, noted "+++" in records (henceforth called pervasive craving).

The drug use pattern during the follow-up is recorded as (a) abstinence, (b) intermittent or occasional drinking, and (c) problem drinking or dependent use (i.e., continued use). For the purpose of this study, we defined abstinent user as those who did not consume any amount of alcohol in the past 1 week; intermittent drinking as those who consumed \<20% of their usual intake per day, never on three successive days, and not having any socio-occupational dysfunction due to alcohol use in the past 1 week; problem drinking as use beyond controlled use including any amount of alcohol use in patients with alcohol-related medical and psychiatric problem.

The follow-up data were extracted from the follow-up notes available in the personal case files of the patients. Data were analyzed for weekly visits till week 4. Cumulative abstinent duration (in days) was calculated for each week. Since many users consumed locally brewed alcohol which can have varied strength of alcohol content, changes in alcohol consumption are recorded in terms of percentage change from pretreatment use.

RESULTS {#sec1-2}
=======

A total of 315 patients of alcohol dependence syndrome were registered during the study period. Subsequently, 223 patients (70.79%) turned up for follow-up by the end of 1 week in the de-addiction clinic. Out of 223 patients, 113 patients of alcohol dependence syndrome who were on baclofen were recruited for the study after applying the inclusion and exclusion criteria for the same. The sociodemographic features are as shown in [Table 1](#T1){ref-type="table"}. The age range of participants was 22--65 years (mean age 41.5 ± 9.8 years), age at dependence was 33.5 (±5.9) years. Approximately, 70% (*n* = 79) of the patients had abstained for a period of at least 1 month since the onset of dependence pattern while 47.8% (*n* = 54) of the patients had taken treatment for alcohol dependence in past. In terms of looking at the motivation of patients, the records showed that 55 patients (48.7%) of the sample were in precontemplation phase of the motivation cycle at baseline. In addition to alcohol dependence as a primary substance of abuse, eight patients (7.1%) had opioid dependence and one each had cannabis and sedative dependence. Family history of substance dependence was reported by 84 patients (73.3%).

###### 

Clinical profile of patients (*n*=113)
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One hundred and thirteen patients who received baclofen, 57 (50.44%) of them were treated at outpatient service and rest were admitted in the ward. The change in dose of baclofen, craving intensity, and alcohol use at each assessment is noted in [Table 2](#T2){ref-type="table"}. The number of patients with pervasive craving at baseline (70.8%) steady decreased to 14.9% by week 4. About 65% of the patients were either abstinent or controlled users by 4 weeks.

###### 

Substance use profile of patients undergoing baclofen course (*n*=113)
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DISCUSSION {#sec1-3}
==========

Baclofen has shown evidence for decrease in withdrawal symptoms as well as reduction in craving.\[[@ref17][@ref19][@ref20][@ref21][@ref22]\] In the present study, we attempted to study changes in craving and alcohol use pattern after prescription of baclofen. The study sample was predominantly male, married, and employed. Although most trials which have used immediate release formulation of baclofen (30 mg/day given in three divided doses),\[[@ref21][@ref22][@ref24]\] we used the sustain release preparation (either 20 mg or 30 mg capsules) which reportedly is an efficacious, convenient, and better-tolerated alternatives to immediate release baclofen.\[[@ref25]\]

All the patients reported craving for alcohol use with 70% reporting pervasive craving at baseline. Within 1 week of baclofen treatment, there was a reduction in intensity of craving from 70.8% (at baseline) to just 22.1% within a week and \<15% at week 4. Many earlier research studies have shown that baclofen treatment reduces craving score as measured by the obsessive--compulsive drinking scale (OCDS; total score, obsessive subscale score, and compulsive subscale score) and the Penn Alcohol Craving Scale.\[[@ref21][@ref26]\]

Unlike acamprosate whose anticraving efficacy takes some time to be evident,\[[@ref27]\] baclofen reduces craving within a week.\[[@ref21][@ref28]\] Although we did escalate the dose of baclofen in some patients who did not have any reduction in craving, about 50% of patients did not need dose escalation beyond 20 mg/day of baclofen. The maximum dose of 40 mg/day was prescribed to \<8.6% of patients. None of the patients in this study reported side effects that warranted discontinuation or dose reduction. Baclofen can be prescribed in larger doses, and many experienced neurologists have used baclofen doses of 300 mg/day for control of spasticity. Two case reports have also described how high-dose of baclofen (140 mg and 270 mg/day) for craving reduction in patients of alcohol dependence.\[[@ref29][@ref30]\] Indeed, recent studies have used doses of 60 mg and 80 mg/day of baclofen for reducing craving among cocaine\[[@ref31]\] and nicotine users.\[[@ref32]\] Currently, no evidence exists on reduced efficacy/tolerability of baclofen in alcohol dependence patients at doses beyond those we prescribed.

The reduction in craving was also accompanied by decrease in alcohol use, with 69% becoming abstinent or intermittent user by week 1 and at least 65% maintaining this pattern by week 4. This finding is remarkable and is very close to two double-blind placebo-controlled baclofen trials\[[@ref22][@ref28]\] in patients of alcohol dependence patients where abstinence was reported as high as 70% and 71.4% in the baclofen arm of the trial. Both these trials were carried in outpatient setting; the former was a 4 week trial while the latter was 12 week trial conducted in those with additional diagnosis of liver cirrhosis. Although 25--35% of patients did not shift from problem drinking to abstinence or intermittent drinking, the cumulative abstinence duration did show a gradual increase over the 4 week period. It must be noted here that those who continue to use alcohol on prescribed doses of baclofen report a minimal increase in sedative effect of alcohol with no increase in positive subjective effects.\[[@ref33]\]

Lorazepam was prescribed to patients, primarily as hypnotic during the 1^st^ week at night time only and continued if the patient continued to have problems related to initiation and maintenance of sleep. Nearly, all patients needed lorazepam for sleep disturbances despite our best efforts to minimize it use. Baclofen, thus, does not appear to influence alcohol withdrawal insomnia even when given as night time dose. Since we did not exclude the patients of other substance dependence (multiple substance users) and patients with comorbid psychiatric illness, a higher dose of lorazepam was needed to induce or maintain sleep in them. To check for unprescribed use of lorazepam by patient, their informants were regularly asked for the same.

Although some patients were already on another anticraving medication (*n* = 17, one on disulfiram \[250 mg/day\], two on naltrexone \[50 mg/day\], and 14 on topiramate \[mean dose 111 mg/day\]), baclofen was added to their regimen as patients had not shown significant decrease in alcohol use or were having persistent craving. These patients did not appear to benefit from baclofen possibly because both topiramate and baclofen are involved in modulating the same (GABAnergic) transmitter system. The possible benefit of baclofen to those with additional diagnosis of opioid dependence, nicotine dependence, or cannabis dependence cannot be made with the available information in our records. No increase in levels of alanine transaminase or aspartate aminotransferase levels was evident although serum biochemistry was assessed only in those with clinical suspicion of hepatic dysfunction.

In India, it is a common clinical scenario for a person with AUD to report to treatment services against his/her will, i.e., on insistence of family members. Such patients tend to minimize the impact of alcohol use in their social, vocational, or interpersonal functioning. While motivation enhancement therapy is recommended in such situations, experience in India suggests that such individuals rarely come back for psychological consultation. We prescribed baclofen in such individuals and interestingly, precontemplators (noted as \'poor motivation\' in records) at initial assessment (*n* = 55) when followed up at week 2 (*n* = 44), reported a reduction in alcohol craving. Pervasive craving reported by 95.5% of this sample at baseline was reported only by 11.4% of patients at week 2. Similarly, alcohol consumption reduced to abstinent or intermittent use in 77.3% of sample at the end of week 2. As previously mentioned, baclofen reduces withdrawal symptoms and craving at initiation consequently making it easier for precontemplators to reduce or stop alcohol use. Thus, baclofen may have a significant impact on treatment of alcoholic population in this country. Its safety and efficacy, even in those with cirrhosis, will encourage management of alcoholism by nonpsychiatric physician.\[[@ref17]\]

The study has few limitations. Assessment of craving and alcohol use is recorded in nonstandard terms. A significant number of patients dropped out at various intervals within the 4 week period although dropout of about 65% by the end of 1 month has been reported by other de-addiction centers in India.\[[@ref34]\] In case of baclofen use in alcoholism, dropouts have cited "lack of medication effect" as the main reason.\[[@ref26]\] In our study, of those who did not follow-up, medical records of at least 68.18% (*n* = 66) of patients reported abstinence/intermittent drinking during the preceding week and 71.11% (*n* = 45) reported abstinence/intermittent drinking in the previous 2 weeks. Although we could not ascertain the reasons of their inability to follow-up for treatment, it is likely to be attributed to problems such as prolonged wait period in hospital, travel hassles, loss of daily wages, and belief that no further treatment is necessary\[[@ref35]\] and not necessarily to "relapse to drinking." Studies related to outcomes in alcohol dependence from India are few and have not included assessment of craving and baseline motivation as factors influencing outcome.\[[@ref36][@ref37][@ref38][@ref39]\]

In summary, our clinical experience with baclofen suggests that it definitively reduces alcohol craving and alcohol consumption in those with alcohol dependence at least in the early period of treatment. It benefits even those who are still in precontemplation stage of motivation. Research has shown that baclofen reduces withdrawal symptoms of alcohol and is safe in those with liver impairment. These findings make baclofen an essential drug for the management of AUDs. Further studies that compare long-term alcohol-related outcome of baclofen with established drugs such as naltrexone and disulfiram are needed.
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